You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

exon 20 insertion mutation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Shanghai (Furmonertinib 160mg, Furmonertinib 240mg)

Recruiting
  • NSCLC
  • Furmonertinib 160mg
  • Furmonertinib 240mg
  • Shanghai, China
    Shanghai Chest hospital
Jan 16, 2023

NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Fairfax, Virginia
    NEXT Virginia
Sep 18, 2023

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

Recruiting
  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 25, 2023

Non-squamous NSCLC Trial (biological, drug, dietary supplement)

Not yet recruiting
  • Non-squamous NSCLC
  • Pembrolizumab
  • +7 more
  • (no location specified)
Feb 20, 2023

Learn About Tests Looking forGene Mutation in Lung Cancer in

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • No Intervention
  • Beijing, China
    Department of Pathology, National Cancer Center/National Clinica
Feb 24, 2023

Locally Advanced or Metastatic NSCLC Trial in Seoul (Osimertinib 80 MG [Tagrisso])

Completed
  • Locally Advanced or Metastatic NSCLC
  • Osimertinib 80 MG [Tagrisso]
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Sep 22, 2021

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

NSCLC Trial in Shanghai (Furmonertinib 240mg, Furmonertinib 160mg)

Withdrawn
  • NSCLC
  • Furmonertinib 240mg
  • Furmonertinib 160mg
  • Shanghai, China
    Shanghai Chest hospital
Oct 17, 2021

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

Recruiting
  • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 21, 2023

NSCLC Trial in China (DZD9008)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Beijing, China
  • +32 more
Jan 26, 2023

NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC Trial in Canada, Hong Kong, United States (tarloxotinib bromide)

Terminated
  • NSCLC, Stage IV
  • +7 more
  • tarloxotinib bromide
  • Irvine, California
  • +13 more
Nov 11, 2021

Non Small Cell Lung Cancer, EGFR Exon 20 Mutation Trial in Worldwide (CLN-081)

Recruiting
  • Non Small Cell Lung Cancer
  • EGFR Exon 20 Mutation
  • Duarte, California
  • +18 more
Nov 11, 2022

NSCLC Trial in Worldwide (Poziotinib)

Active, not recruiting
  • NSCLC
  • Phoenix, Arizona
  • +62 more
Jan 27, 2023

Osimertinib for Patients With Non-Small Cell Lung Cancer

Not yet recruiting
  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • EGFR Exon20 Insertion Mutations
  • Baoding, China
  • +23 more
Aug 23, 2022

Mobocertinib in Adults With Lung Cancer in China (MEANING)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • No Intervention
  • Shanghai, China
    Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai J
May 9, 2023

NSCLC Trial in China (DZD9008, Pemetrexed+carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Beijing, China
  • +40 more
Dec 20, 2022

NSCLC Trial (Mobocertinib 160 mg)

Approved for marketing
  • Carcinoma, Non-Small-Cell Lung
  • Mobocertinib 160 mg
  • (no location specified)
Sep 28, 2022

EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

Recruiting
  • EGFR Exon 20 Mutation
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 12, 2022

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • NSCLC
  • (no location specified)
Jul 17, 2022

NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

Recruiting
  • Non-Small Cell Lung Cancer
  • +5 more
  • Toripalimab
  • +3 more
  • Guanzhou, Guangdong, China
    Guangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023

NSCLC Trial in China, Korea, Republic of (Poziotinib)

Terminated
  • NSCLC
  • Beijing, China
  • +25 more
Nov 16, 2020

NSCLC Trial in Amsterdam, Groningen, Maastricht (Afatinib, Cetuximab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Amsterdam, North-Holland, Netherlands
  • +3 more
Oct 19, 2021

Non-small Cell Lung Cancer EGFR Exon 20 Insertion

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
    • Cordoba, Andalucia, Spain
    • +14 more
    Nov 1, 2022

    NSCLC Trial in Worldwide (Afatinib)

    Completed
    Has Results
    • NSCLC
    • Köln, Germany
    • +4 more
    Aug 23, 2022

    A Chart Review Study of Adults With Advanced NSCLC

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
      • (no location specified)
      Aug 1, 2022